

Efficacy #234

Please type a plus sign (+) inside this box - Approved for use through 10/31/2002. OMB No. 061-0031
U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	09/101,518
				Filing Date	January 11, 1996
				First Named Inventor	Li
				Group Art Unit	1646
				Examiner Name	Pak, M.
Sheet	1	of	1	Attorney Docket Number	PF218US

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	U.S. Patent Document	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Kinds Code: Number	(if known)	MM-DD-YYYY	

FOREIGN PATENT DOCUMENTS					
Examiner Initials	Cite No.	Foreign Patent Document	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ¹ Number ²	Kinds Code ³	MM-DD-YYYY	

OTHER REFERENCES - NON-PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			
MOP	CK	R&D SYSTEMS TECHNICAL DATA SHEET, "Monoclonal Anti-Human CXCR3 Antibody," Catalog Number MAB160, December 2002			
	CL	BD PHARMINGEN TECHNICAL DATA SHEET, "CD183 (CXCR3) Purified Mouse Ann-Human Monoclonal Antibody," Catalog Number 337183, March 2002			
	CM	QIN et al., "The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions," J. Clin. Invest. 101(4):746-753 (1998).			
	CN	GARCIA-LÓPEZ et al., "CXCR3 chemokine receptor distribution in normal and inflamed tissues expression on activated lymphocytes, endothelial cells, and dendritic cells," Lab. Invest. 81(3):409-418 (2001)			
MOP	CO	JINQUAN et al., "CXCR3 expression and activation of eosinophils. role of IFN-γ-Inducible Protein 10 and Monokine Induced by IFN-γ," J. Immunol. 163:1548-1556 (2000).			

Examiner Signature	MICHAEL YAK	Date Considered	5-30-03
--------------------	-------------	-----------------	---------

¹ Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. See Standard Kinds of U.S. Patent Documents. ³ Enter Office that issues the document, by the publication code (WIPO Standard ST 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.10, if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.